前沿生物(688221) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥5,670,338.94, representing a decrease of 1.64% compared to the same period last year[5] - The net profit attributable to shareholders was -¥59,241,597.75, indicating a significant loss[5] - Total operating revenue for Q1 2022 was ¥5,670,338.94, a decrease of 1.65% compared to ¥5,765,128.93 in Q1 2021[21] - Net profit for Q1 2022 was a loss of ¥59,241,597.75, compared to a loss of ¥46,817,219.62 in Q1 2021, reflecting a deterioration in performance[22] - Basic and diluted earnings per share were both -¥0.16, compared to -¥0.12 in the previous year[22] Research and Development - Research and development expenses totaled ¥35,825,300.07, which accounted for 631.80% of operating revenue, an increase of 168.84 percentage points year-on-year[6] - R&D expenses rose significantly to ¥35,825,300.07, representing a 34.2% increase from ¥26,690,332.38 in Q1 2021[21] Cash Flow - Cash flow from operating activities was -¥34,410,228.06, indicating negative cash flow[5] - Cash flow from operating activities showed a net outflow of ¥34,410,228.06, an improvement from a net outflow of ¥52,829,171.95 in Q1 2021[24] - Cash flow from investing activities resulted in a net outflow of ¥108,334,993.14, compared to a net outflow of ¥336,861,458.41 in the same quarter last year[26] - Cash flow from financing activities generated a net inflow of ¥22,362,704.35, contrasting with a net outflow of ¥9,737,188.72 in Q1 2021[26] - The ending cash and cash equivalents balance was ¥676,921,936.92, an increase from ¥439,513,758.63 at the end of Q1 2021[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,469,395,642.38, down 2.50% from the end of the previous year[6] - As of March 31, 2022, the company's total assets amounted to CNY 2,469,395,642.38, a decrease from CNY 2,532,632,487.06 at the end of 2021[19] - The company's cash and cash equivalents were CNY 683,265,236.92, down from CNY 800,854,646.14 at the end of 2021, reflecting a decrease of approximately 14.7%[17] - The total current liabilities decreased to CNY 351,857,755.31 from CNY 399,490,531.69, indicating a reduction of about 11.9%[19] - The company's total liabilities were CNY 697,282,000.67, slightly down from CNY 702,406,533.36, showing a decrease of approximately 0.2%[19] - The total equity attributable to shareholders decreased to CNY 1,772,113,641.71 from CNY 1,830,225,953.70, a decline of about 3.2%[19] - The company's inventory increased to CNY 44,324,884.55 from CNY 38,617,406.68, representing an increase of approximately 14.8%[17] - The accounts receivable decreased to CNY 15,633,045.09 from CNY 22,344,127.51, reflecting a decline of about 30.2%[17] - The company's long-term borrowings increased to CNY 20,170,000.00 from CNY 7,500,000.00, indicating a significant increase of approximately 168.9%[19] - The company's non-current assets totaled CNY 977,043,161.15, slightly up from CNY 955,120,879.92, showing an increase of about 2.3%[18] - The company's total current assets were CNY 1,492,352,481.23, down from CNY 1,577,511,607.14, a decrease of approximately 5.4%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,576[13] - The largest shareholder, Jianmu Pharmaceutical Co., Ltd., held 19.63% of the shares, totaling 70,638,750 shares[13] Fixed Assets - The company experienced a 440.08% increase in fixed assets, primarily due to the capitalization of an office building[9] Other Income - The company reported other income of ¥3,177,366.47, up from ¥1,012,952.34 in Q1 2021, indicating improved financial management[21]